RVNC - Revance Therapeutics: A Robust Pick For 2020
Today, we will be studying why Revance Therapeutics (RVNC) is an attractive investment for 2020.
Company Overview
Revance is a biotechnology company focused on developing innovative long-lasting neuromodulators. The company’s lead investigational product, DAXI (Daxibotulinumtoxin A for Injection), is being evaluated in a range of aesthetic and therapeutic indications. The company is also working on the development of Botox biosimilar in the pre-clinical stage. Today, Revance anticipates several significant milestones in 2020.
A neuromodulator is a large and fast-growing market opportunity.
According to UBS Specialty Pharmaceuticals Handbook April 2018, the global neuromodulator market